What is the 13F Pro Quality Score for BBIO?

13F Pro ranks BridgeBio Pharma, Inc. (BBIO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BBIO's current score at https://13fpro.ai/company/BBIO (free sign-up required for the full ranking).

Which hedge funds own the most BBIO stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of BBIO include Jupiter Topco, Kohlberg Kravis Roberts & Co. L.P., FARALLON CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/BBIO as soon as new 13F filings post.

Where does 13F Pro source BBIO data?

All BridgeBio Pharma, Inc. fundamentals and ownership data come directly from SEC EDGAR. BridgeBio Pharma, Inc. files with the SEC under CIK 1743881. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BBIO in?

BridgeBio Pharma, Inc. (BBIO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BBIO research updated on 13F Pro?

BBIO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BridgeBio Pharma, Inc.(BBIO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqlarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 1743881 BBIO stock profile & AI dashboard →

13F Pro Quality Score

36.9/100

Rank #2,248 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

96.1/100

Profitability

8.0/100

Balance Sheet

3.0/100

Earnings Quality

28.4/100

Free Cash Flow

8.3/100

Institutional Flow

42.3/100

Revenue Scale

43.2/100

Dilution Risk

6.8/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why BBIO Scores 37/100

exact factor attribution · 2026-09-11

BBIO's composite is driven by revenue growth, held back by profitability and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.2 pts

96th pct

Earnings growth

+0.7 pts

63th pct

Institutional flow

-0.4 pts

42th pct

Scale

-1.0 pts

43th pct

Shareholder dilution

-2.2 pts

7th pct

Earnings quality

-2.2 pts

28th pct

Capital efficiency

-4.7 pts

3th pct

Free cash flow

-6.3 pts

8th pct

Profitability

-6.3 pts

8th pct

Latest change (2026-08-13): 32 → 32 · ↓ Institutional flow 59→50

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

BBIO Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for BridgeBio Pharma, Inc. (BBIO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BBIO at 36.9/100 on a 32-signal composite quality model, placing it at rank #2,248 of 2,961 stocks — the bottom half of the AI-ranked universe. BBIO scores in the top quartile across revenue growth (96.1). Areas of concern include balance sheet strength (3.0) and profitability (8.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), BridgeBio Pharma, Inc. reports quarterly revenue of $243.7M, net income of $-155.9M, free cash flow of $-71.5M. Top institutional holders of BBIO by reported 13-F value include Jupiter Topco, Kohlberg Kravis Roberts & L.P., FARALLON CAPITAL MANAGEMENT, based on the most recent SEC filings. BBIO trades on the Nasdaq exchange and files with the SEC under CIK 1743881. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BridgeBio Pharma, Inc. directly from SEC EDGAR. BridgeBio Pharma, Inc.'s 13F Pro composite quality score has ranged between 7 and 37 since 2021, currently 36.9 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

Revenue

Q2 2026

$243.7M

Net Income

Q2 2026

$-155.9M

Free Cash Flow

Q2 2026

$-71.5M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+126.3% YoY

$502.1MFY 2025

FY22 $77.6MFY23 $9.3MFY24 $221.9MFY25 $502.1M

Operating Income

+11.7% YoY

$-523.4MFY 2025

FY22 $-512.2MFY23 $-607.4MFY24 $-593.0MFY25 $-523.4M

EPS (Diluted)

-31.3% YoY

$-3.78FY 2025

FY22 $-3.26FY23 $-3.95FY24 $-2.88FY25 $-3.78

Total Assets

+1.8% YoY

$936.0MFY 2025

FY22 $623.0MFY23 $546.4MFY24 $919.3MFY25 $936.0M

Total Debt

+359.0% YoY

$2.01BFY 2025

FY22 $431.0MFY23 $446.4MFY24 $437.3MFY25 $2.01B

Op. Cash Flow

+14.4% YoY

$-445.9MFY 2025

FY22 $-419.5MFY23 $-527.7MFY24 $-520.7MFY25 $-445.9M

Free Cash Flow

+14.3% YoY

$-447.0MFY 2025

FY22 $-424.3MFY23 $-529.0MFY24 $-521.7MFY25 $-447.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$502.1M +126.3%	$221.9M +2285.3%	$9.3M -88.0%	$77.6M +11.4%	$69.7M +745.1%	$8.2M
Operating Income	$-523.4M +11.7%	$-593.0M +2.4%	$-607.4M -18.6%	$-512.2M +11.2%	$-576.6M -21.5%	$-474.5M
EPS (Diluted)	$-3.78 -31.3%	$-2.88 +27.1%	$-3.95 -21.2%	$-3.26 +16.4%	$-3.90 -2.6%	$-3.80
Total Assets	$936.0M +1.8%	$919.3M +68.3%	$546.4M -12.3%	$623.0M -38.5%	$1.01B +43.9%	$703.6M
Total Debt	$2.01B +359.0%	$437.3M -2.0%	$446.4M +3.6%	$431.0M +0.1%	$430.8M +351.8%	$95.3M
Operating Cash Flow	$-445.9M +14.4%	$-520.7M +1.3%	$-527.7M -25.8%	$-419.5M +15.8%	$-497.9M -24.6%	$-399.7M
Free Cash Flow	$-447.0M +14.3%	$-521.7M +1.4%	$-529.0M -24.7%	$-424.3M +17.0%	$-511.2M -25.5%	$-407.2M

Get alerted when BBIO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BridgeBio Pharma, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BBIO

Jupiter Topco LLC
$1.1B14,110,278 sh
Kohlberg Kravis Roberts & Co. L.P.
$987.7M13,260,971 sh
FARALLON CAPITAL MANAGEMENT LLC
$800.1M10,743,063 sh
BlackRock, Inc.
$766.2M10,287,156 sh
VIKING GLOBAL INVESTORS LP
$741.0M9,949,219 sh
VANGUARD CAPITAL MANAGEMENT LLC
$588.3M7,898,973 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$570.3M7,656,722 sh
WELLINGTON MANAGEMENT GROUP LLP
$395.4M5,308,924 sh
TWO SIGMA INVESTMENTS, LP
$351.7M4,722,185 sh
Aisling Capital Management LP
$341.8M4,589,611 sh

Fund	Value	Shares
Jupiter Topco LLC	$1.1B	14,110,278
Kohlberg Kravis Roberts & Co. L.P.	$987.7M	13,260,971
FARALLON CAPITAL MANAGEMENT LLC	$800.1M	10,743,063
BlackRock, Inc.	$766.2M	10,287,156
VIKING GLOBAL INVESTORS LP	$741.0M	9,949,219
VANGUARD CAPITAL MANAGEMENT LLC	$588.3M	7,898,973
VANGUARD PORTFOLIO MANAGEMENT LLC	$570.3M	7,656,722
WELLINGTON MANAGEMENT GROUP LLP	$395.4M	5,308,924
TWO SIGMA INVESTMENTS, LP	$351.7M	4,722,185
Aisling Capital Management LP	$341.8M	4,589,611

Companies Similar to BBIO

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

MIRM

Mirum Pharmaceuticals, Inc.

AI score

Very similar · 30 shared holders

Frazier Life Sciences Management, L.P.Polar Capital Holdings Plc Clearbridge Investments, LLC

Guardant Health, Inc.

AI score

Very similar · 33 shared holders

LINDEN ADVISORS LP Hood River Capital Management LLC LORD, ABBETT & CO. LLC

MDGL

MADRIGAL PHARMACEUTICALS, INC.

AI score

Very similar · 30 shared holders

Polar Capital Holdings Plc Hood River Capital Management LLC LORD, ABBETT & CO. LLC

CYTK

CYTOKINETICS INC

AI score

Very similar · 33 shared holders

Polar Capital Holdings Plc Frazier Life Sciences Management, L.P.Capital Research Global Investors

RYTM

RHYTHM PHARMACEUTICALS, INC.

AI score

Very similar · 26 shared holders

Polar Capital Holdings Plc PRIMECAP MANAGEMENT CO/CA/Clearbridge Investments, LLC

INSM

INSMED Inc

AI score

Very similar · 26 shared holders

Hood River Capital Management LLC Polar Capital Holdings Plc Bellevue Group AG

ARWR

ARROWHEAD PHARMACEUTICALS, INC.

AI score

Very similar · 27 shared holders

Hood River Capital Management LLC SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC LORD, ABBETT & CO. LLC

SNDX

Syndax Pharmaceuticals Inc

AI score

Very similar · 14 shared holders

Hood River Capital Management LLC Aisling Capital Management LP Catalio Capital Management, LP

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BBIO on your watchlist

Track score changes the day BridgeBio Pharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BBIO a good stock to buy?

13F Pro's AI-powered analysis of BridgeBio Pharma, Inc. (BBIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BBIO are available on the BBIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BBIO is classified as a large company.

Which hedge funds own BBIO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BBIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BridgeBio Pharma, Inc.'s investment landscape.